SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. - Wikidata - wikimedia - TriplyDB

SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve.

SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve.

http://www.wikidata.org/entity/Q30313107

about

The Lotus dilemma-respond to paravalvular leakage, but not answering pacemaker implantations?Managing aortic stenosis with TAVI or surgery: risk assessement and long-term outcome.From Cinderella to centre stage: valvular heart disease on the move.The year in cardiology 2017: valvular heart disease.

P2860

Q47154854-BBED1A38-F425-4586-ACE4-41D4EDA2CE42 Q50066462-F8AFE070-C69F-406D-8A38-E7D493757EC2 Q50087865-B1A22B29-90E2-4344-B401-9B8ABAB9B31A Q50193639-BE6EFC47-1231-4C5F-88CE-5EE05FE7C191

P2860

SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve.

http://www.wikidata.org/entity/Q30313107

description

2017 nî lūn-bûn

@nan

2017 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@ast

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@en

type

label

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@ast

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@en

prefLabel

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@ast

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@en

P1433

Q30313107-B01D3F82-63F0-46E9-B915-1410B311A998

P1476

Q30313107-AE19510C-AFA0-482A-A7B5-F1518656E104

P2093

Q30313107-0D96A58F-6484-436D-B706-A6D891B6D425

Q30313107-2FB32CB1-E5EB-4CAC-819F-79C2080BCAE7

Q30313107-44AD0D39-A031-4BA3-BA5D-EE5377362633

Q30313107-61EEDF5F-5125-47F6-AE95-29AC23DF3CCF

Q30313107-92487A67-7266-46F6-BA69-F21080DA10AE

Q30313107-A260257D-DDF2-4465-A01F-A827BF0F99E0

Q30313107-BB9DC75E-9B4F-4F74-8912-8D4B2AD26101

Q30313107-C4D264D3-866F-4DFF-BCC4-C1A8AFC5E519

P2860

Q30313107-0A9EA792-0F3E-4802-BA71-F7DBB492F833

Q30313107-2883E1E8-A51E-4BD8-BE72-9E7A83E93530

Q30313107-3BF9D25A-44DE-45E7-A70B-29C63D42FD51

Q30313107-57305412-AEDA-4803-BBA6-E205D011A0BD

Q30313107-5E384DBB-2117-4D96-AAAB-C5BC694D017A

Q30313107-6BEE89F5-C9C9-429C-B557-58BC81EDCA67

Q30313107-806C59E9-EC46-4A7C-AB00-4ADED3BA32E4

Q30313107-8CBA2BD8-26B5-42B8-8D0C-0DA9EA8D207B

Q30313107-D64AA03A-031A-443B-A6B5-3AE8A4B5692F

Q30313107-D979358C-B511-4E3E-8945-937D41781D9A

P304

Q30313107-4608EFEA-DE03-495F-B8C4-0C49B85679D7

P31

Q30313107-3961DA7A-94B5-42BE-98BE-7D93878B8257

P356

Q30313107-60D7677A-2651-46C6-9F16-6438F42169E8

P433

Q30313107-FF2BD535-5CED-4619-B090-AF43B96B7211

P478

Q30313107-A3F2194F-FABE-4B0B-9FFC-34590D413FA8

P50

Q30313107-8E52D907-3C52-43BB-92A9-EE3AF6C6C920

P577

Q30313107-58D51D76-B03E-40D3-BC1A-CB50522F35FB

P698

Q30313107-0F0E31D2-933E-4F64-8C39-51176805C750

P932

Q30313107-369C7AE1-C82C-4A94-A185-86EF5638D40B

P356

P1433

European Heart Journal

P1476

SOURCE 3: 1-year outcomes post ...... ble transcatheter heart valve.

@en

P2093

Alec Vahanian

http://www.w3.org/2001/XMLSchema#string

Franz-Josef Neumann

http://www.w3.org/2001/XMLSchema#string

Gerhard Schymik

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tarantini

http://www.w3.org/2001/XMLSchema#string

Helmut Baumgartner

http://www.w3.org/2001/XMLSchema#string

José Luis Zamorano

http://www.w3.org/2001/XMLSchema#string

Nicolas Dumonteil

http://www.w3.org/2001/XMLSchema#string

Olaf Wendler

http://www.w3.org/2001/XMLSchema#string

P2860

One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis.

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

SOURCE 3 Registry: Design and 30-Day Results of the European Postapproval Registry of the Latest Generation of the SAPIEN 3 Transcatheter Heart Valve.

One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.

Prospective Multicenter Evaluation of the Direct Flow Medical Transcatheter Aortic Valve System: 12-Month Outcomes of the Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Ste

European experience with the second-generation Edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry.

1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study.

Clinical impact of acute kidney injury on short- and long-term outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis.

Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study.

Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve.

P304

2717-2726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHX294

http://www.w3.org/2001/XMLSchema#string

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28605423

http://www.w3.org/2001/XMLSchema#string

P932

5837400

http://www.w3.org/2001/XMLSchema#string